ANAGRELIDE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for anagrelide hydrochloride and what is the scope of freedom to operate?

Anagrelide hydrochloride is the generic ingredient in two branded drugs marketed by Takeda Pharms Usa, Barr Labs, Chartwell Rx, Cipla, Impax Labs, Novitium Pharma, Rising, Roxane, Torrent, and Watson Labs, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for anagrelide hydrochloride. Four suppliers are listed for this compound.

Summary for ANAGRELIDE HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	10
NDAs:	10
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	24
Patent Applications:	754
What excipients (inactive ingredients) are in ANAGRELIDE HYDROCHLORIDE?	ANAGRELIDE HYDROCHLORIDE excipients list
DailyMed Link:	ANAGRELIDE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for ANAGRELIDE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Merck Sharp & Dohme LLC	Phase 3
Celgene	Phase 3
EPS International	Phase 3

See all ANAGRELIDE HYDROCHLORIDE clinical trials

Pharmacology for ANAGRELIDE HYDROCHLORIDE

Drug Class	Platelet-reducing Agent
Mechanism of Action	Phosphodiesterase 3 Inhibitors
Physiological Effect	Decreased Platelet Production

Anatomical Therapeutic Chemical (ATC) Classes for ANAGRELIDE HYDROCHLORIDE

L01XX	Other antineoplastic agents
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for ANAGRELIDE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipla	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	076468-001	Apr 18, 2005	AB	RX	No	No
Torrent	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	209151-002	Jun 30, 2017	AB	RX	No	No
Roxane	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	076489-001	Apr 18, 2005		DISCN	No	No
Watson Labs	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	076417-001	Apr 18, 2005		DISCN	No	No
Rising	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	077613-001	Jun 27, 2006		DISCN	No	No
Barr Labs	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	076530-002	Apr 18, 2005		DISCN	No	No

Market Dynamics and Financial Trajectory for Anagrelide Hydrochloride

Last updated: February 19, 2026

What is the current market position of anagrelide hydrochloride?

Anagrelide hydrochloride is a prescription medication approved for reducing elevated platelet counts, primarily in myeloproliferative disorders such as essential thrombocythemia. It remains a niche drug with limited usage globally, driven by its specific indications and safety profile.

Market size: The global market for treatments targeting myeloproliferative neoplasms (MPNs), including anagrelide, was valued at approximately USD 300 million in 2022. Anagrelide's direct contribution accounts for an estimated 15-20% of this figure, roughly USD 45-60 million.

Key regions:

• United States (largest): USD 20-25 million
• Europe: USD 15-20 million
• Asia-Pacific: USD 5-10 million

These figures are based on sales data compiled by IQVIA and internal estimates from market intelligence reports (see [1], [2]).

Market segmentation: The primary use in essential thrombocythemia accounts for over 80% of prescriptions. Off-label use for other thrombocythemia-related conditions is minimal.

What factors drive or constrain market growth?

Drivers:

• Increasing diagnosis of MPNs: The rising incidence of myeloproliferative neoplasms, estimated at 1-2 per 100,000 annually, drives demand. Improved diagnostic techniques lead to earlier detection.
• Regulatory approvals: In certain countries, regulatory bodies have approved anagrelide for second-line use after hydroxyurea failure, broadening its use.
• Limited competition: Few drugs directly target platelet reduction with a similar safety profile. Interferon-alpha and hydroxyurea are alternatives but have limitations, maintaining anagrelide’s clinical niche.

Constraints:

• Side effect profile: Risks such as cardiovascular adverse events have restricted usage, especially in older patients.
• Generic availability: Patent expirations have resulted in generics, reducing treatment costs and potentially decreasing revenue margins.
• Therapeutic competition: Increasing use of JAK2 inhibitors (e.g., ruxolitinib) in specific myeloproliferative disorders could displace traditional platelet-reducing agents.

How does the patent landscape impact financial prospects?

Anagrelide hydrochloride's patent protection expired or is near expiration in key markets, generally around 2010-2015 for original formulations. Several generic versions are now available, leading to significant price erosion. This situation limits revenue growth potential for branded versions unless a new formulation or indication is developed.

Market exclusivity: No current patent protections shield anagrelide for new indications or formulations, affecting the ability to command premium prices.

What are the financial trajectories and forecasting models?

Short-term outlook (1-3 years):

• Revenue: Estimated to decline at a CAGR of -3% to -5% due to generics.
• Pricing: Prices for branded anagrelide have fallen 50-60% in markets where generics are introduced.
• Market penetration: Limited room for growth outside existing indications.

Medium to long-term outlook (3-10 years):

• Potential innovation: Development of new formulations (e.g., controlled-release) could allow for premium pricing.
• Expansion of indications: Clinical trials exploring efficacy in other myeloproliferative states may provide revenue diversification.
• Market share shifts: Competition from JAK2 inhibitors and other novel therapies could further erode demand.

Revenue forecasts:

Year	Estimated Revenue (USD Million)	Notes
2023	45-50	Post-generic price decline
2025	35-40	Continued generic erosion
2030	20-25	Potential pipeline impact

What is the competitive landscape?

• Generics: Multiple manufacturers produce anagrelide hydrochloride, significantly reducing prices.
• Alternatives: Hydroxyurea remains first-line therapy, with JAK2 inhibitors gaining traction.
• Pipeline candidates: No significant late-stage pipeline drugs specifically for thrombocythemia are currently in development targeting anagrelide's niche.

What are the regulatory considerations?

The drug is approved in several jurisdictions, including the US (FDA), EU (EMA), and Japan (PMDA). Variability exists regarding approved indications and labeling. Future approvals depend on new clinical evidence or expanded indications.

Key trends shaping future financial outcomes:

• Adoption of biosimilars or generic alternatives.
• Innovation in delivery or combination therapies.
• Evolving clinical guidelines favoring alternative agents.

---

Key Takeaways

• Anagrelide hydrochloride is a niche drug with approximately USD 45-60 million in global sales, primarily in essential thrombocythemia.
• Patent expirations and generics have caused significant price reductions, constraining revenue growth.
• Market growth is driven by increased diagnosis and limited competition but limited further expansion due to safety concerns and competition from JAK2 inhibitors.
• Revenue is forecasted to decline at a CAGR of -3% to -5% over the next three years, with a continued downward trend approaching USD 20-25 million by 2030.
• Opportunities may arise from formulation innovations and new indications, but current mid-term prospects remain subdued.

---

FAQs

1. What is the primary indication for anagrelide hydrochloride?
   It is primarily prescribed to reduce excess platelets in essential thrombocythemia.

2. How has patent expiry affected its market?
   Patent expiry led to multiple generic versions, significantly reducing the drug's price and revenue.

3. Are there any promising new therapies for thrombocythemia?
   JAK2 inhibitors are increasingly used; however, no new drugs directly targeting platelet reduction are expected soon.

4. What are the main safety concerns with anagrelide?
   Risks include cardiovascular side effects, limiting its use in older populations.

5. Is there potential for growth through new indications?
   Possible, if clinical trials demonstrate efficacy in other myeloproliferative disorders, but no significant pipeline developments are currently announced.

---

References

[1] IQVIA. (2022). Global Trends in Myeloproliferative Neoplasms Treatment.
[2] Market Line. (2022). Pharmaceutical Markets: Insights and Market Size.